- Home
- TRVI vs ECAT Comparison
TRVI vs ECAT Comparison
Compare TRVI & ECAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRVI | ECAT |
|---|---|---|
| Founded | 2011 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TRVI | ECAT |
|---|---|---|
| Price | $11.16 | $13.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $20.38 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 564.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.20% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.32 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.85 | $13.35 |
| 52 Week High | $14.39 | $17.14 |
Technical Indicators
Market Signals| Indicator | TRVI | ECAT |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 26.87 |
| Support Level | $10.04 | N/A |
| Resistance Level | $11.78 | $16.64 |
| Average True Range (ATR) | 0.74 | 0.23 |
| MACD | -0.13 | -0.09 |
| Stochastic Oscillator | 12.35 | 4.58 |
Price Performance
Historical ComparisonAbout TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.